BOT has to pay substantial royalities (license payments) to their licensor. They will look to make a one-off payment to the licensor in order to reduce these royalties. It will be cheaper (but riskier) to do it now, as there is no FDA approval / USA revenue. It ultimately means they can keep more of the income from sales.
Ann: Trading Halt, page-23
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
34.0¢ |
Change
0.020(6.25%) |
Mkt cap ! $617.9M | |||
| Open | High | Low | Value | Volume |
| 32.5¢ | 34.3¢ | 32.5¢ | $1.814M | 5.424M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 489055 | 33.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 34.5¢ | 340303 | 4 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| BOT (ASX) Chart |